FrancophonIA/ELRC3.0 huggingface dataset:
English: If you inject Palynziq with another injectable medicine that contains PEG, such as PEGylated medroxyprogesterone acetate, you may have an allergic reaction.
Slovenian: Če zdravilo Palynziq vbrizgate z drugim zdravilom za vbrizgavanje, ki vsebuje PEG (kot je pegiliran medroksiprogesteron acetat), lahko pride do alergijske reakcije.
English: Study 301 an open-label randomised (1:1), multi-centre study of patients with PKU to assess the safety and tolerability of self-administered Palynziq in an induction/titration/maintenance dose regimen.
Slovenian: Študija 301 je nezaslepljena, randomizirana (1 : 1), multicentrična študija bolnikov s PKU za ocenjevanje varnosti in prenašanja samoapliciranega zdravila Palynziq pri režimu odmerjanja za indukcijo/titracijo/vzdrževalno zdravljenje.
English: • A healthcare provider will monitor you for at least 1 hour after you get Palynziq for signs and symptoms of an allergic reaction.
Slovenian: • Zdravstveni delavec bo vaše stanje spremljal vsaj 1 uro po uporabi zdravila Palynziq, če bi prišlo do znakov in simptomov alergijske reakcije.
English: Additional findings in rabbits included increased abortions, foetal malformations and embryo/foetal lethality.
Slovenian: Dodatne ugotovitve pri zajcih so vključevale večje število splavov, malformacije ploda in večjo smrtnost zarodka/ploda.
English: 2 Hypersensitivity reactions cover a group of terms, including acute systemic hypersensitivity reactions, and can manifest as a range of symptoms including angioedema, serum sickness, rash, and urticaria.
Slovenian: 2 Preobčutljivostne reakcije zajemajo skupino izrazov, vključno z akutnimi sistemskimi preobčutljivostnimi reakcijami, ter se lahko izrazijo v obliki različnih simptomov, kot so angioedem, serumska bolezen, izpuščaj in urtikarija.
English: * Anabaena variabilis rAvPAL produced by recombinant DNA technology in Escherichia coli.
Slovenian: * rAvPAL iz bakterije Anabaena variabilis, pridobljen s tehnologijo rekombinantne DNK v sevu Escherichia coli.
English: A total of 164 previously-treated Palynziq patients (152 patients from Study 301, and 12 patients from other Palynziq trials) continued treatment for up to 13 weeks.
Slovenian: Skupno 164 bolnikov, ki so se predhodno zdravili z zdravilom Palynziq (152 bolnikov iz študije 301 in 12 bolnikov iz drugih preskušanj z zdravilom Palynziq), je zdravljenje nadaljevalo do 13 tednov.
English: Of the 5 serum sickness episodes where time to onset was evaluable, 1 episode occurred within 1 hour of injection and 4 episodes occurred between 24 hours and up to 5 days following injection.
Slovenian: Od 5 epizod serumske bolezni, pri katerih je bilo mogoče oceniti čas do nastopa, se je 1 epizoda pojavila v 1 uri od injiciranja, 4 epizode pa so se pojavile med 24 urami in 5 dnevi od injiciranja.
English: Patients should be monitored every 2 weeks until blood phenylalanine levels are within a clinically acceptable range (see section 4.4, Hypophenylalaninaemia).
Slovenian: Bolnike je treba spremljati vsaka 2 tedna, dokler ravni fenilalanina v krvi niso v klinično sprejemljivem razponu (glejte poglavje 4.4 Hipofenilalaninemija).
English: Twelve patients (11 patients from Study 301) aged 16 up to 18 years received Palynziq treatment.
Slovenian: Dvanajst bolnikov (11 bolnikov iz študije 301), starih od 16 do 18 let, se je zdravilo z zdravilom Palynziq.
English: As a consequence, these patients were more likely to develop hypophenylalaninaemia.
Slovenian: Zato je bil razvoj hipofenilalaninemije pri teh bolnikih verjetnejši.
English: • Your doctor will continue to check your blood phenylalanine levels during treatment and may adjust your dose of Palynziq or ask you to change your diet.
Slovenian: • Zdravnik vam bo med zdravljenjem preverjal raven fenilalanina v krvi in vam morda prilagodil odmerek zdravila Palynziq ali naročil, da spremenite dieto.
English: • Your doctor will then slowly increase your dose and/or how often you inject Palynziq.
Slovenian: • Zdravnik vam bo nato počasi povečeval odmerek in/ali pogostnost vbrizgavanja zdravila Palynziq.
English: Therefore, a reduction in pegvaliase dose should be considered in patients experiencing hypophenylalaninaemia despite appropriate levels of protein intake (see section 4.2).
Slovenian: Zato bi bilo treba o zmanjšanju odmerka pegvaliaze razmisliti pri bolnikih, ki imajo hipofenilalaninemijo kljub ustreznim ravnem vnosa beljakovin (glejte poglavje 4.2).
English: PREPARING FOR INJECTION
Slovenian: PRIPRAVA NA INJEKCIJO
English: Time to response (achieving blood phenylalanine levels ≤ 600 micromol/l) varies among patients.
Slovenian: Čas do odziva (vzpostavitev ravni fenilalanina v krvi ≤ 600 mikromolov/l) se med bolniki razlikuje.
English: Patients who developed hypophenylalaninaemia during the studies were advised to increase their protein intake from intact foods and/or reduce Palynziq dose.
Slovenian: Bolnikom, pri katerih se je med študijami razvila hipofenilalaninemija, se je svetovalo povečanje vnosa beljakovin iz nepredelane hrane in/ali zmanjšanje odmerka zdravila Palynziq.
English: Do not use a Palynziq syringe more than once.
Slovenian: Injekcijske brizge z zdravilom Palynziq ne uporabite več kot enkrat.
English: Of the 261 patients in Study 301, 11 patients were aged between 16 and 18 years at enrolment.
Slovenian: Od 261 bolnikov v študiji 301 je bilo 11 bolnikov ob vključitvi v študijo starih med 16 in 18 let.
English: The purpose of the PEGylation of rAvPAL is to reduce immune recognition of the rAvPAL bacterial protein, and increase the half-life.
Slovenian: Namen pegilacije beljakovine rAvPAL je zmanjšanje imunskega prepoznavanja bakterijske beljakovine rAvPAL in povečanje razpolovnega časa.
English: Allergic reactions occur very commonly (may affect more than 1 in 10 people) and range in severity.
Slovenian: Alergijske reakcije se pojavijo zelo pogosto (pojavijo se lahko pri več kot 1 od 10 bolnikov) in se razlikujejo glede na resnost.
English: • If you need more than 1 injection for your daily dose, the injection sites should be at least 5 centimetres away from each other (see Figures E and F).
Slovenian: • Če za dnevni odmerek potrebujete več kot 1 injekcijo, morajo biti mesta vbrizgavanja med seboj oddaljena vsaj 5 centimetrov (glejte sliki E in F).
English: Treatment with Palynziq should be directed by physicians experienced in the management of PKU.
Slovenian: Zdravljenje z zdravilom Palynziq mora voditi zdravnik z izkušnjami pri obravnavi PKU.
English: Of the 9 angioedema episodes where time to onset was evaluable, 5 episodes occurred within 24 hours of injection, 4 episodes occurred between 24 hours and up to 29 days of injection.
Slovenian: Od 9 epizod angioedema, pri katerih je bilo mogoče oceniti čas do nastopa, se je 5 epizod pojavilo v 24 urah od injiciranja, 4 epizode pa so se pojavile med 24 urami in 29 dnevi od injiciranja.
English: • Palynziq pre-filled syringes come in 3 different strengths: 2.5 mg, 10 mg, and 20 mg.
Slovenian: • Zdravilo Palynziq je v napolnjenih injekcijskih brizgah na voljo v 3 različnih jakostih: 2,5 mg, 10 mg in 20 mg.
English: You may see a drop of liquid on the tip of the needle.
Slovenian: Na konici igle lahko vidite kapljico tekočine.
English: Three injection site reactions consistent with granulomatous skin lesions were reported (each reaction occurring in one patient): granulomatous dermatitis (occurred 15 months after Palynziq treatment and lasted 16 days), xanthogranuloma (occurred 12 months after Palynziq treatment and lasted 21 months), and necrobiosis lipoidica diabeticorum (occurred 9 months after Palynziq treatment and lasted 9 months).
Slovenian: Poročali so o treh reakcijah na mestu injiciranja z znaki granulomatozne kožne lezije (vsaka reakcija se je pojavila pri enem bolniku): granulomatoznem dermatitisu (pojavil se je 15 mesecev po zdravljenju z zdravilom Palynziq in trajal 16 dni), ksantogranulomu (pojavil se je 12 mesecev po zdravljenju z zdravilom Palynziq in trajal 21 mesecev) in lipoidni diabetični nekrobiozi (pojavila se je 9 mesecev po zdravljenju z zdravilom Palynziq in trajala 9 mesecev).
English: All episodes resolved without sequelae (see Immunogenicity section).
Slovenian: Vse epizode so se odpravile brez posledic (glejte poglavje Imunogenost).
English: Palynziq is given as an injection under the skin (subcutaneous injection).
Slovenian: Zdravilo Palynziq se daje kot podkožna injekcija (subkutana injekcija).
English: Blood phenylalanine1
Slovenian: Fenilalanin v krvi1
English: Following cellular uptake, the metabolism of phenylalanine ammonia lyase (PAL) is expected to occur via catabolic pathways and be degraded into small peptides and amino acids; the PEG molecule is metabolically stable and expected to be separated from PAL protein and primarily eliminated by renal filtration.
Slovenian: Po vnosu v celice se pričakuje, da se fenilalanin amoniakliaza (PAL) metabolizira prek katabolnih poti ter se razgradi v majhne peptide in aminokisline; molekula PEG je metabolno stabilna ter naj bi se ločila od beljakovine PAL in primarno izločila s filtracijo v ledvicah.
English: In Palynziq clinical trials, the majority of patients developed anti-PEG IgM and IgG antibodies after treatment with Palynziq (see section 4.8).
Slovenian: V kliničnih preskušanjih zdravila Palynziq so se pri večini bolnikov po zdravljenju z zdravilom Palynziq razvila protitelesa proti PEG razredov IgM in IgG (glejte poglavje 4.8).
English: 1 Blood phenylalanine level prior to initiating treatment with Palynziq.
Slovenian: 1 Raven fenilalanina v krvi pred začetkom zdravljenja z zdravilom Palynziq.
English: 10 mg once a week 10 mg twice a week 10 mg four times a week 10 mg daily
Slovenian: 10 mg enkrat tedensko 10 mg dvakrat tedensko 10 mg štirikrat tedensko 10 mg dnevno zelen bat
English: Ten out of the 16 patients who experienced an acute systemic hypersensitivity reaction were rechallenged and 4 patients had at least one recurrence.
Slovenian: Deset od 16 bolnikov, pri katerih je prišlo do akutne sistemske preobčutljivostne reakcije, je znova prejelo zdravilo in pri 4 bolnikih je prišlo do vsaj ene ponovitve.
English: These reactions were consistent with a Type III immune-complex mediated hypersensitivity mechanism and were most frequent in the early phases of treatment (during the induction and titration periods) when the early immune response was dominated by PEG IgM, PEG IgG and PAL IgM responses and C3/C4 levels were at their lowest.
Slovenian: Te reakcije so imele znake mehanizma preobčutljivosti tipa III, posredovanega z imunskimi kompleksi, in so bile najpogostejše v zgodnjih fazah zdravljenja (med indukcijo in titracijo), ko so v zgodnjem imunskem odzivu prevladovali odzivi protiteles IgM proti PEG, IgG proti PEG in IgM proti PAL, ravni faktorja C3/C4 pa so bile najnižje.
English: Patients in the 20 mg once daily randomised arm reached their maintenance dose at a median time of 10 weeks (range: 9 to 29 weeks) and patients in the 40 mg once daily arm reached their maintenance dose at a median time of 11 weeks (range: 10 to 33 weeks).
Slovenian: Bolniki v randomizirani skupini z 20 mg enkrat na dan so svoj vzdrževalni odmerek dosegli pri mediani časa 10 tednov (razpon: 9 do 29 tednov), bolniki v skupini s 40 mg enkrat na dan pa so svoj vzdrževalni odmerek dosegli pri mediani časa 11 tednov (razpon: od 10 do 33 tednov).
English: In clinical trials, serum sickness was reported in 7 out of 285 (2%) patients.
Slovenian: V kliničnih preskušanjih so o serumski bolezni poročali pri 7 od 285 (2 %) bolnikov.
English: Your healthcare provider will tell you which syringe, or combination of syringes, to use.
Slovenian: Zdravstveni delavec vam bo povedal, katero injekcijsko brizgo oziroma kombinacijo injekcijskih brizg morate uporabiti.
English: • Do not remove the needle cap until you are ready to inject Palynziq.
Slovenian: • Pokrovčka igle ne odstranite, dokler niste pripravljeni na injekcijo zdravila Palynziq.
English: Symptoms of mood (confusion, fatigue, depression, tension-anxiety, vigour, and anger domains) were evaluated using the Profile of Mood States (POMS) tool that has been modified to be specific to PKU (PKU-POMS).
Slovenian: Simptomi v povezavi z razpoloženjem (povezani z zmedenostjo, utrujenostjo, depresijo, napetostjo/tesnobo, zavzetostjo in jezo) so se ocenili s profilom razpoloženjskih stanj („Profile of Mood States“ - POMS), ki je bil posebej prilagojen za PKU (PKU-POMS).
English: 1 Post-baseline phenylalanine values were mapped to the closest monthly visit (i.e. within a 1-month window).
Slovenian: 1 Vrednosti fenilalanina, pridobljene po izhodiščni vrednosti, so bile pripisane najbližjemu obisku v enem mesecu (tj. v obdobju 1 meseca).
English: • 54% of patients, 69% of patients, and 72% of patients reached blood phenylalanine level
Slovenian: • 54 % bolnikov, 69 % bolnikov in 72 % bolnikov doseglo raven fenilalanina v krvi, ki je znašala
English: Pegvaliase induced anti-PEG IgM and IgG responses were detected in the majority of patients (98%) and titres peaked at 1 to 3 months after treatment initiation and then returned to baseline levels in most patients by 6 to 9 months after treatment initiation (see section 4.5).
Slovenian: Odzivi protiteles proti PEG razredov IgM in IgG, ki jih je inducirala pegvaliaza, so bili zaznani pri večini bolnikov (98 %), pri čemer so titri dosegli največjo vrednost od 1 do 3 mesece po začetku zdravljenja, nato pa so se pri večini bolnikov vrnili na izhodiščne vrednosti od 6 do 9 mesecev po začetku zdravljenja (glejte poglavje 4.5).
English: Based on animal studies, hypophenylalaninaemia in pregnant women with PKU treated with Palynziq may be associated with adverse foetal outcomes (see sections 4.6 and 5.3).
Slovenian: Na podlagi študij na živalih je lahko hipofenilalaninemija pri nosečnicah s PKU, ki se zdravijo z zdravilom Palynziq, povezana z neželenimi posledicami za plod (glejte poglavji 4.6 in 5.3).
English: Effect of Palynziq on other PEGylated injectable medicinal products
Slovenian: Vpliv zdravila Palynziq na druga pegilirana zdravila za injiciranje
English: • The goal is to reach a daily dose that lowers your blood phenylalanine levels to within the target range of 120 to 600 micromol/l and does not cause too many side effects.
Slovenian: • Cilj je doseči dnevni odmerek, ki vam bo raven fenilalanina v krvi znižal na ciljni razpon 120600 mikromolov/l in vam ne bo povzročil preveč neželenih učinkov.
English: Mean (SD) for apparent volume of distribution (Vz/F) at steady state following 20 mg and 40 mg doses was 26.4 L (64.8 L) and 22.2 L (19.7 L) respectively.
Slovenian: Povprečje (SD) navideznega volumna porazdelitve (Vz/F) pri stanju dinamičnega ravnovesja po odmerku 20 mg in 40 mg je znašalo 26,4 l (64,8 l) in 22,2 l (19,7 l), v tem zaporedju.
English: Use a new pre-filled syringe for your injection.
Slovenian: Za injekcijo uporabite novo napolnjeno injekcijsko brizgo.
English: 1 patient did not complete the RDT due to adverse event transitioned to the long-term extension period and the remaining 4 patients who did not complete phenylalanine assessment within the window for Week 8 (Day 43 to 56).
Slovenian: 1 bolnik zaradi neželenega dogodka ni zaključil obdobja RDT in je prešel na zdravljenje v dolgotrajnem podaljšanem obdobju, za preostale 4 bolnike pa se ni pridobila ocena fenilalanina v obdobju 8. tedna (43. do 56. dan).
English: Uncontrolled blood phenylalanine levels (hyperphenylalaninaemia) before and during pregnancy are associated with increased risk for miscarriage, major birth defects (including microcephaly and major cardiac malformations), intrauterine foetal growth retardation and future intellectual disability with low IQ.
Slovenian: Neuravnane ravni fenilalanina v krvi (hiperfenilalaninemija) pred in med nosečnostjo so povezane s povečanim tveganjem za spontani splav, hudimi prirojenimi okvarami (vključno z mikrocefalijo in hudimi srčnimi napakami), intrauterinim zastojem rasti ploda in poznejšo umsko prizadetostjo z nizkim IQ.
English: The pre-filled syringe includes an automatic needle guard.
Slovenian: Napolnjena injekcijska brizga vključuje samodejni ščitnik igle.
English: High sensitivity CRP levels increased6
Slovenian: Preiskave zvišanje ravni CRP visoke občutljivosti6
English: Injection of other medicines that contain PEG while using Palynziq Palynziq includes an ingredient called polyethylene glycol (PEG).
Slovenian: Vbrizgavanje drugih zdravil, ki vsebujejo PEG, med uporabo zdravila Palynziq Zdravilo Palynziq vsebuje sestavino z imenom polietilen glikol (PEG).
English: Step 14: Slowly move your thumb up to release the plunger allowing the needle to automatically be covered by the syringe body (see Figure N).
Slovenian: 14. korak: Palec počasi dvignite in s tem sprostite bat, da bo telo injekcijske brizge samodejno prekrilo iglo (glejte sliko N).
English: After injection, the needle automatically retracts into the needle guard safely covering the needle.
Slovenian: Po injiciranju se igla samodejno uvleče v ščitnik igle, ki jo varno prekrije.
English: It is normal to see an air bubble.
Slovenian: Prisotnost zračnih mehurčkov je normalna.
English: Patients and the observer should be instructed to recognise the signs and symptoms of acute systemic hypersensitivity reactions, in the proper emergency use of the adrenaline injection device, and the requirement to seek immediate medical care.
Slovenian: Bolnike in opazovalca je treba poučiti o znakih in simptomih akutnih sistemskih preobčutljivostnih reakcij, ustrezni uporabi pripomočka za injiciranje adrenalina v nujnih primerih ter o tem, da je treba poiskati takojšnjo medicinsko pomoč.
English: Example of steps to reach your blood phenylalanine goal Palynziq dose and how often to take it
Slovenian: Primer korakov za doseganje ciljne ravni fenilalanina v krvi Odmerek zdravila Palynziq in pogostnost jemanja
English: The most common cutaneous reactions (at least 5% of patients) reported were pruritus (37 patients; 13%), rash (33 patients; 12%), erythema (15 patients; 5%), and urticaria (15 patients; 5%).
Slovenian: Najpogostejše kožne reakcije (vsaj 5 % bolnikov), o katerih so poročali, so bile pruritus (37 bolnikov; 13 %), izpuščaj (33 bolnikov; 12 %), eritem (15 bolnikov; 5 %) in urtikarija (15 bolnikov; 5 %).
English: Eligibility period
Slovenian: Obdobje ocenjevanja primernosti
English: 2 Based on the mixed model repeated measures (MMRM) method, with treatment arm, visit, and treatment arm-by-visit interaction (the time profile of blood phenylalanine changes is assessed separately for each treatment arm) as factors adjusting for baseline blood phenylalanine concentration.
Slovenian: 2 Glede na metodo mešanega modela ponovljene meritve (MMRM), pri čemer so skupina zdravljenja, obisk in interakcija skupina zdravljenja-obisk (časovni profil sprememb ravni fenilalanina v krvi je ocenjen ločeno za posamezno skupino zdravljenja) dejavniki prilagoditve izhodiščne koncentracije fenilalanina v krvi.
English: Patients with lower antibody titres for all antibody analytes including NAb had higher pegvaliase concentrations due to less immune-mediated pegvaliase clearance.
Slovenian: Pri bolnikih z nižjo vrednostjo titrov protiteles za vse analite protiteles, vključno z NAb, je bila koncentracija pegvaliaze višja, in sicer zaradi manjšega očistka pegvaliaze z imunskim odzivom.
English: The active substance is a covalent conjugate of the protein phenylalanine ammonia lyase (rAvPAL)* with NHS-methoxypolyethylene glycol (NHS-PEG).
Slovenian: Zdravilna učinkovina je kovalentni konjugat beljakovine fenilalanin amoniakliaze (rAvPAL)* z NHS-metoksipolietilen glikolom (NHS-PEG).
English: The underlying mechanism for acute systemic hypersensitivity reactions observed in clinical trials was non-IgE mediated Type III (immune-complex mediated) hypersensitivity (see section 4.8).
Slovenian: Mehanizem akutnih sistemskih preobčutljivostnih reakcij, ki so bile opažene v kliničnih preskušanjih, je bila preobčutljivost tipa III, ki ni bila posredovana s protitelesi razreda IgE, temveč z imunskimi kompleksi (glejte poglavje 4.8).
English: Of the 164 patients that entered the eligibility period of Study 302, 86 patients met the eligibility criterion (achieved at least 20% mean blood phenylalanine reduction from pre-treatment baseline at their randomised dose within 13 weeks) and continued to the RDT, 12 patients discontinued treatment, and 57 patients did not enter the RDT and continued Palynziq treatment in the long-term extension period of Study 302, where they were allowed to increase dose.
Slovenian: Od 164 bolnikov, ki so bili vključeni v obdobje ocenjevanja primernosti študije 302, je 86 bolnikov izpolnjevalo merilo primernosti (doseženo vsaj 20-odstotno znižanje povprečne ravni fenilalanina v krvi glede na izhodiščno vrednost pred zdravljenjem pri randomiziranem odmerku v 13 tednih) in so bili vključeni v obdobje preskušanja z randomiziranim prenehanjem dajanja zdravila (RDT), 12 bolnikov se je prenehalo zdraviti, 57 bolnikov pa ni bilo vključenih v obdobje RDT in je nadaljevalo zdravljenje z zdravilom Palynziq v dolgotrajnem podaljšanem obdobju študije 302, v katerem je bilo mogoče povečati odmerek.
English: The contribution of maternal phenylalanine depletion to the incidence of embryo-foetal developmental effects was not evaluated.
Slovenian: Vpliv znižanja ravni fenilalanina pri materi na incidenco učinkov na razvoj zarodka/ploda se ni ocenjeval.
English: All 16 patients who experienced acute systemic hypersensitivity reactions tested negative for pegvaliase-specific IgE at or near the time of the acute systemic hypersensitivity reactions episode.
Slovenian: Vseh 16 bolnikov, pri katerih so se pojavile akutne sistemske preobčutljivostne reakcije, je imelo negativne rezultate za protitelesa razreda IgE, specifična za pegvaliazo, v času, ko je prišlo do epizode akutne sistemske preobčutljivostne reakcije.
English: Patients should be instructed to carry adrenaline injection device with them at all times during Palynziq treatment.
Slovenian: Bolnikom je treba naročiti, naj imajo med zdravljenjem z zdravilom Palynziq pripomoček za injiciranje adrenalina vedno pri sebi.
English: Arthralgia episodes were managed with concomitant medicinal products (e.g., nonsteroidal anti-inflammatory drugs, glucocorticoids, and/or antipyretic), dose reduction (4% of episodes), treatment interruption (4% of episodes), or treatment withdrawal (0.6% of episodes), and 97% of arthralgia episodes resolved by the time of the data cut-off.
Slovenian: Epizode artralgije so bile obravnavane s sočasno uporabo zdravil (npr. nesteroidnimi protivnetnimi zdravili, glukokortikoidi in/ali antipiretiki), zmanjšanjem odmerka (4 % epizod), prekinitvijo zdravljenja (4 % epizod) ali trajno prekinitvijo zdravljenja (0,6 % epizod), pri čemer se je 97 % epizod artralgije odpravilo do datuma prenehanja zbiranja podatkov.
English: • The patient information pack should contain: o The patient information leaflet o The guide for patients and trained observers o The patient alert card
Slovenian: • Komplet z informacijami za bolnika mora vsebovati: o navodilo za uporabo; o vodnik za bolnike in usposobljene opazovalce; o opozorilno kartico za bolnika.
English: 1 ml pre-filled syringe made of Type I borosilicate glass, equipped with a stainless steel 26 gauge needle, needle safety device, polypropylene plunger rod, and chlorobutyl rubber syringe stopper with fluoropolymer coating.
Slovenian: 1-mililitrska napolnjena injekcijska brizga iz borosilikatnega stekla tipa I, opremljena z iglo 26 G iz nerjavnega jekla, ščitnikom igle, batom iz polipropilena in zamaška injekcijske brizge iz klorobutilne gume s prevleko iz fluoropolimera.
English: Acute systemic hypersensitivity reactions were managed by administration of adrenaline (44%; 11/25 episodes), corticosteroids (56%; 14/25 episodes), antihistamines (56%; 14/25 episodes), and/or oxygen (8%; 2/25 episodes).
Slovenian: Akutne sistemske preobčutljivostne reakcije so bile obravnavane z uporabo adrenalina (44 %; 11/25 epizod), kortikosteroidov (56 %; 14/25 epizod), antihistaminikov (56 %; 14/25 epizod) in/ali kisika (8 %; 2/25 epizod).
English: Refer to the adrenaline product information for complete information.
Slovenian: Za celotne informacije glejte informacije o adrenalinu.